Thursday, April 27, 2017 1:22:45 PM
The article today even states this:
"With this pathway, the FDA uses animal efficacy studies and human safety data as the basis for product approval."
As we all know, there is only one safety study being conducted. Here is the study called: "A Study to Evaluate the Safety of Intramuscular Injections of PLX-R18 in Subjects With Incomplete Hematopoietic Recovery Following Hematopoietic Cell Transplantation"- Website:
https://clinicaltrials.gov/ct2/show/NCT03002519
The study will not be completed until 2019.
Everyone is talking about efficacy, and all of the papers confirm this focus and the great outcomes.. That data is sound. What is in question is how will humans respond to the pharmacodynamics of PLX-R18.
I hate to throw water on the flames, but this is a real fact that governments will require. Yes we will get bumps up along the way, but, in my humble opinion, we may be faced with a longer period of time until the safety data is satisfied.
Please don't all of you gang up on me at one time!!!
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM